system
infect
caus
mdr
fungi
grow
global
health
concern
estim
approxim
million
case
dissemin
mycos
occur
annual
associ
high
mortal
fungal
pathogen
major
caus
hospitalacquir
particularli
among
surgic
patient
indwel
increas
risk
system
fungal
infect
also
associ
biolog
therapi
treatment
inflammatori
autoimmun
among
fungal
infect
candida
spp
frequent
caus
organ
case
candidiasi
occur
increas
risk
infect
associ
defect
innat
immun
neutropenia
grow
incid
mdr
candida
spp
infect
contribut
increas
mortal
rate
associ
system
major
risk
factor
system
candidiasi
presenc
biofilm
commonli
colon
implant
medic
devic
venou
cathet
biofilm
notori
resist
antifung
therapi
sourc
blood
born
failur
develop
agent
select
eukaryot
pathogen
imped
clinic
introduct
new
current
three
class
antifung
drug
reli
upon
treatment
invas
fungal
infect
polyen
azol
echinocandin
introduc
nearli
year
ago
recent
approv
class
antifung
limit
associ
use
current
avail
agent
includ
limit
activ
seriou
advers
side
lack
activ
emerg
mdr
fungal
pathogen
underscor
urgent
need
develop
new
approach
treatment
fungal
macrocycl
peptid
contain
amino
acid
cyclic
backbon
stabil
tridisulfid
numer
natur
occur
isoform
express
old
world
monkey
owm
macaqu
baboon
peptid
absent
new
world
monkey
ape
prototyp
rhesu
macaqu
effect
preclin
model
polymicrobi
e
coli
sarscoronaviru
mous
model
p
aeruginosa
induc
cystic
endotoxininduc
lung
recent
studi
report
potent
fungicid
vitro
mdr
c
albican
nonalbican
candida
spp
includ
emerg
pathogen
candida
current
studi
evalu
antifung
activ
plankton
cell
biofilm
drug
sensit
mdr
c
albican
strain
vitro
found
peptid
fungicid
form
strain
test
efficaci
therapeut
mous
model
system
candidiasi
analyz
effect
peptid
treatment
surviv
fungal
clearanc
inflammatori
biomark
infect
mediat
drugsensit
mdr
isol
c
albican
base
find
potent
rapidli
fungicid
sever
c
albican
nonalbican
candida
spp
includ
mdr
test
activ
peptid
blastospor
two
caspofungin
caspo
resist
c
albican
clinic
isol
well
genet
defin
drugsensit
refer
strain
minimum
inhibitori
concentr
mic
minim
fungicid
concentr
mfc
determin
demonstr
casporesist
clinic
isol
resist
fluconazol
fluco
strain
strain
resist
caspo
drug
sensit
tabl
consist
previou
fungicid
three
strain
micsmfc
rang
tabl
mfc
mic
tabl
time
activ
fluco
three
strain
test
standard
condit
tabl
previous
report
drug
sensit
c
albican
mdr
c
albican
strain
rapidli
concentrationdepend
kill
relat
show
similar
time
concentrationdepend
kill
casporesist
peptid
concentr
low
kill
input
blastospor
within
min
peptid
exposur
fig
steril
incub
mixtur
min
incub
condit
caspo
show
littl
activ
either
strain
fig
antifung
activ
fungal
blastospor
also
evalu
presenc
mous
serum
presenc
serum
inact
c
albican
peptid
concentr
tabl
signific
find
discuss
sinc
fungal
biofilm
gener
resist
convent
antifung
analyz
activ
fluco
caspo
biofilm
c
albican
mdr
isol
agent
test
effect
biofilm
format
incub
fungal
cell
prepar
agent
prior
adhes
h
adhes
plastic
matur
h
biofilm
establish
fig
inhibit
biofilm
drug
sensit
time
point
less
effect
caspo
preadhes
condit
fluco
effect
concentr
howev
much
effect
fluco
h
assay
fig
note
antifung
effect
caspo
h
biofilm
reduc
concentr
consist
socal
paradox
eagl
effect
previous
also
inhibit
biofilm
format
mdr
strain
unlik
highli
resist
fluco
condit
test
concentrationdepend
biofilm
inhibit
similar
caspo
fig
data
demonstr
effect
fungal
biofilm
vitro
activ
approxim
caspo
c
albican
organ
fluco
studi
efficaci
vivo
evalu
establish
model
system
candidiasi
use
c
albican
immunocompet
immunosuppress
mous
model
employ
preclin
studi
system
candidiasi
sinc
mani
preliminari
studi
employ
latter
model
conduct
efficaci
studi
refer
antifung
drug
immunocompet
balbc
mice
mice
challeng
iv
blastospor
rapidli
produc
dissemin
candidiasi
colon
major
organ
manner
resembl
system
candidiasi
condit
typic
caus
termin
morbid
day
salin
treat
control
analyz
effect
singl
mgkg
dose
administ
iv
sc
ip
immedi
iv
fungal
challeng
ip
salin
vehicl
control
fluco
caspo
administ
ip
mgkg
use
drug
compar
salin
treat
challeng
mice
die
becam
termin
moribund
requir
euthanasia
day
wherea
singl
dose
treatment
caspo
p
fluco
p
effect
enhanc
surviv
fig
singl
dose
significantli
enhanc
surviv
regardless
rout
administr
p
ip
sc
p
iv
significantli
differ
fluco
treatment
fig
caspo
treatment
superior
fluco
treatment
p
case
fig
subsequ
studi
antifung
agent
administ
ip
circumv
potenti
confound
effect
result
treatment
rout
infect
iv
experi
tolerabilitytox
evalu
ip
dose
balbc
mice
mgkg
daili
day
mgkg
everi
day
day
mgkg
mice
toler
dose
level
clinic
normal
observ
period
least
day
follow
last
escal
dose
next
evalu
administr
singl
ip
dose
rang
mgkg
immedi
iv
fungal
challeng
except
lowest
mgkg
shown
highest
dose
test
mgkg
fig
treatment
enhanc
surviv
significantli
p
compar
salin
control
fig
enhanc
surviv
curv
follow
singl
dose
mgkg
statist
equival
fig
administr
mgkg
fluco
fig
b
interestingli
dose
mgkg
less
effect
fluco
p
dose
mgkg
p
case
see
suppl
tabl
analyz
effect
delay
treatment
follow
fungal
challeng
compar
dose
time
iv
fungal
challeng
one
hour
delay
reduc
surviv
benefit
fig
nevertheless
even
treatment
delay
h
singl
ip
dose
mgkg
result
enhanc
surviv
compar
salin
control
p
fig
howev
surviv
enhanc
achiev
peptid
administr
delay
h
h
data
shown
determin
whether
multipl
dose
administr
would
improv
surviv
mice
delay
treatment
format
mice
challeng
iv
c
albican
treat
ip
day
day
mgkg
caspo
fluco
first
dose
agent
given
h
fungal
infect
agent
markedli
enhanc
surviv
p
fig
effect
enhanc
surviv
fluco
nearli
equival
caspo
bodi
weight
long
term
survivor
day
treatment
cohort
differ
statist
uninfect
mice
day
post
infect
otherwis
clinic
normal
fig
data
shown
ascertain
system
level
found
effect
vivo
plasma
level
evalu
h
period
singl
mgkg
iv
ip
inject
balbc
mice
fig
twocompart
model
best
describ
iv
data
mean
maximum
concentr
cmax
time
reach
maximum
concentr
tmax
ip
inject
h
respect
data
indic
slowli
absorb
ip
bioavail
suppl
tabl
goodnessoffit
plot
final
pharmacokinet
model
shown
supplementari
fig
plasma
level
also
analyz
min
addit
daili
mgkg
ip
dose
administ
day
instanc
level
statist
differ
obtain
singl
dose
indic
accumul
plasma
cours
sever
inject
fig
note
ip
cmax
valu
fold
lower
mic
c
albican
tabl
moreov
serum
mic
c
albican
indic
antifung
efficaci
peptid
vivo
direct
antifung
effect
fungal
burden
candidem
mice
determin
quantifi
cfu
kidney
homogen
anim
treat
ip
mgkg
fungal
burden
quantifi
day
pi
day
pi
singl
treatment
markedli
reduc
fungal
burden
compar
salin
treat
control
wherein
fungal
burden
continu
increas
day
observ
period
fig
neutrophil
repres
first
line
defens
invas
candidiasi
suscept
system
diseas
markedli
increas
persist
system
diseas
also
associ
greatli
elev
level
proinflammatori
administr
uninfect
mice
littl
effect
blood
cytokin
leukocyt
peptid
treatment
candidem
mice
significantli
p
increas
blood
neutrophil
count
h
pi
fig
interestingli
time
point
increas
blood
neutrophil
fold
mice
p
howev
day
salin
treat
candidem
mice
mark
leukocytosi
neutrophil
count
treat
mous
cohort
significantli
p
lower
essenti
equival
observ
cohort
h
time
point
fig
consist
find
treatment
candidem
mice
result
signific
reduct
blood
proinflammatori
cytokin
implic
candida
sepsi
tnf
day
pi
effect
level
elev
candidem
mice
fig
alter
level
cytokin
mice
assess
effect
treatment
later
diseas
cours
analyz
fungal
burden
blood
leukocyt
inflammatori
cytokin
treat
infect
mice
day
pi
moribund
salin
treat
anim
euthan
pi
fig
b
treatment
markedli
reduc
kidney
fungal
burden
p
peptid
treatment
substanti
effect
treatment
fluco
p
fig
note
cultur
organ
detect
kidney
treat
mice
fungal
clearanc
accompani
homeostat
normal
circul
granulocyt
markedli
elev
moribund
salinetr
control
fig
treat
mice
level
tnf
normal
uninfect
control
fig
complement
homeostat
effect
tnf
observ
day
pi
fig
assess
whether
effect
drug
sensit
c
albican
extend
drug
resist
isol
mice
infect
iv
casporesist
c
albican
treat
ip
mgkg
caspo
fluco
per
day
day
begin
pi
fig
rather
balbc
mice
use
c
albican
challeng
studi
mous
strain
employ
wiederhold
et
al
assess
caspofungin
efficaci
shown
fig
agent
significantli
p
improv
surviv
compar
salin
control
superior
caspo
p
fluco
fig
surviv
endpoint
analysi
day
pi
superior
fluco
p
caspo
p
fungal
burden
determin
kidney
long
term
survivor
caspo
flucotr
cohort
euthan
day
moribund
mice
surviv
studi
fig
agent
test
significantli
p
reduc
fungal
burden
rel
moribund
salin
control
fig
sever
factor
includ
indiscrimin
overus
antifung
increas
use
immunosuppress
therapi
nosocomi
colon
hospit
patient
acceler
emerg
mdr
strain
sever
public
health
threat
gain
worldwid
attent
introduct
echinocandin
nearli
two
decad
ago
provid
valuabl
altern
azol
polyen
mdr
strain
resist
echinocandin
diagnos
increas
highlight
need
new
therapeut
approach
studi
present
suggest
macrocycl
peptid
express
leukocyt
rhesu
macaqu
may
repres
new
therapeut
modal
base
efficaci
system
candidiasi
includ
diseas
mediat
caspofunginresist
mdr
strain
c
albican
prototyp
known
backbon
cycliz
polypeptid
anim
kingdom
natur
isoform
acid
macrocycl
stabil
six
cystein
tridisulfid
core
like
host
defens
peptid
hdp
discov
screen
antimicrobi
activ
lysat
rhesu
macaqu
leukocyt
reveal
close
relat
isoform
rtd
broadli
bactericid
fungicid
vitro
c
albican
cryptococcu
report
kill
candida
spp
vitro
mechan
tempor
link
cell
death
exampl
rapidli
min
permeabil
c
albican
propidium
iodid
induc
atp
releas
reactiv
oxygen
speci
plankton
moreov
fungicid
mdr
c
albican
non
albican
candida
report
first
time
effect
plankton
cell
biofilm
drug
sensit
mdr
c
albican
vitro
howev
mic
higher
cmax
plasma
level
obtain
follow
singl
multipl
dose
regimen
mice
presenc
mous
serum
mic
least
fold
higher
plasma
cmax
valu
therefor
highli
unlik
efficaci
mous
system
candidiasi
direct
antifung
effect
rather
mediat
hostdirect
mechan
produc
mark
surviv
enhanc
superior
obtain
fluco
accompani
effici
fungal
clearanc
consist
hostdirect
mechan
highli
effect
system
candidiasi
drug
sensit
mdr
strain
c
albican
pharmacolog
basi
efficaci
candidemia
yet
determin
data
present
suggest
peptid
administr
may
promot
mobil
neutrophil
blood
level
cell
significantli
elev
treat
candidem
mice
fig
specul
earli
phase
neutrophilia
contribut
reduct
system
fungal
burden
detect
earli
day
singl
treatment
note
neutrophil
play
import
role
host
defens
c
albican
infect
via
phagocytosi
format
neutrophil
extracellular
treatment
candidem
mice
also
profound
effect
inflammatori
cytokin
cours
infect
day
pi
treat
mice
singl
dose
mark
reduct
tnf
compar
salin
treat
anim
addit
later
stage
diseas
cours
treatment
markedli
prolong
surviv
mice
level
normal
compar
moribund
salinetr
control
accompani
signific
reduct
blood
neutrophil
monocyt
thu
treatment
candidem
mice
induc
transient
neutrophilia
follow
profound
reduct
fungal
burden
compar
salin
control
p
regard
treatment
markedli
superior
fluco
fig
parallel
peptid
treatment
homeostat
normal
granulocyt
inflammatori
cytokin
effect
system
candidiasi
consist
result
studi
peptid
analyz
model
e
coli
polymicrobi
p
aeruginosa
murin
sar
coronaviru
studi
therapeut
modifi
cours
diseas
efficaci
associ
modul
patholog
inflamm
therapeut
pharmacolog
properti
system
candidiasi
suggest
peptid
modifi
host
damagerespons
framework
articul
consist
model
treatment
stimul
neutrophilia
earli
infect
suppress
inflammatori
cytokin
promot
homeostat
restor
blood
granulocyt
level
proinflammatori
cytokin
chronic
elev
salin
treat
candidem
mice
also
consist
model
find
doseeffect
relationship
invert
u
shown
increas
efficaci
dose
level
increas
mgkg
mark
decreas
efficaci
dose
mgkg
fig
e
note
ip
dose
least
mgkg
well
toler
uninfect
mice
result
suggest
higher
level
peptid
less
well
toler
candidem
mice
elev
concentr
overli
immunosuppress
studi
requir
delin
pkpharmacodynam
relationship
underli
invert
u
effect
treatment
system
candidiasi
despit
remark
vitro
properti
hdp
effort
develop
therapeut
met
limit
barrier
encount
includ
lack
peptid
stabil
toxic
advers
proinflammatori
properti
poor
bioavail
context
antifung
therapeut
awar
two
report
demonstr
peptid
efficaci
system
candidiasi
first
tavar
et
al
use
plant
defensin
prophylaxi
model
show
iv
administr
mgkg
peptid
given
h
prior
iv
infect
c
albican
strain
reduc
fungal
burden
infect
impact
surviv
evalu
efficaci
mous
candidiasi
recent
analog
bovin
bactenecin
evalu
mous
candidiasi
daili
intraperiton
administr
mgkg
begin
h
retroorbit
infect
clinic
isol
c
albican
modestli
improv
surviv
day
pi
accompani
similarli
modest
reduct
renal
fungal
note
sever
small
nonpeptid
hdpmimic
design
scott
diamond
colleagu
activ
vitro
sever
flucoresist
candida
spp
effect
c
albican
system
studi
first
show
therapeut
efficaci
eg
long
term
surviv
accompani
fungal
clearanc
natur
occur
peptid
system
candidiasi
find
present
demonstr
promot
fungal
clearanc
suppress
patholog
inflamm
effect
augment
host
respons
infect
drug
sensit
mdr
c
albican
strain
note
highli
stabl
serum
fungal
nontox
result
thu
provid
templat
design
bioinspir
macrocycl
compound
may
contribut
unmet
need
new
antifung
therapi
method
method
perform
accord
relev
feder
state
institut
guidelin
anim
use
protocol
approv
univers
southern
california
usc
institut
anim
care
use
committe
iacuc
protocol
refer
strain
c
albican
obtain
american
type
cultur
collect
caspofungin
resist
clinic
isol
c
albican
kindli
provid
dr
nathan
wiederhold
fungu
test
laboratori
univers
texa
health
scienc
center
san
antonio
tx
highli
pure
hydrochlorid
produc
solid
phase
peptid
synthesi
caspofungin
fluconazol
purchas
sigmaaldrich
st
loui
mo
dissolv
mgml
acet
acid
antifung
drug
prepar
steril
water
anim
inject
peptid
antifung
drug
dilut
filter
steril
salin
solut
c
albican
strain
test
fluconazol
caspofungin
microdilut
broth
accord
clinic
laboratori
standard
institut
clsi
document
except
mm
mop
use
place
mm
mop
describ
overnight
cultur
harvest
centrifug
wash
twice
pb
ph
suspend
test
medium
rpmi
medium
mm
mop
mm
lglutamin
incub
conduct
flat
bottom
microtit
plate
greiner
bioon
monro
nc
contain
ml
test
medium
per
well
duplic
ml
aliquot
serial
twofold
dilut
peptid
antifung
drug
dispens
well
inocul
ml
fungal
cell
suspens
contain
cfu
plate
incub
hour
determin
use
spectramax
plate
reader
minim
inhibitori
concentr
mic
defin
lowest
agent
concentr
complet
inhibit
growth
determin
absorb
minim
fungicid
concentr
mfc
determin
plate
ypd
plate
well
mic
assay
without
cell
growth
first
well
measur
turbid
correspond
aliquot
noagent
control
mic
incub
condit
filament
occur
allow
accur
cfu
count
plate
ypd
plate
incub
h
mfc
report
lowest
concentr
peptid
antifung
drug
kill
input
organ
mic
mfc
also
perform
presenc
mous
serum
serum
prepar
blood
collect
cardiac
punctur
balbc
mice
coagul
room
temperatur
serum
collect
centrifug
g
min
follow
g
min
dilut
equal
volum
yeast
inoculum
mic
test
medium
describ
kinet
candidacid
activ
determin
peptid
concentr
rang
use
liquid
suspens
assay
describ
overnight
cultur
c
albican
grown
midlog
phase
yeast
pepton
dextros
broth
ypd
difco
approxim
cfuml
incub
caspofungin
suspend
mm
pipe
ph
plu
mm
glucos
pg
plate
shake
rpm
time
interv
sampl
dilut
fold
pg
buffer
aliquot
plate
onto
ypd
agar
plate
teknova
surviv
organ
quantifi
coloni
count
incub
h
fungicid
activ
caspofungin
similarli
determin
whole
blood
citrat
anticoagul
blood
obtain
cardiac
punctur
mice
approxim
cfuml
c
albican
incub
caspofungin
plate
whole
blood
volvol
final
shake
rpm
h
sampl
dilut
mm
pipe
ph
contain
ypd
aliquot
plate
onto
ypd
agar
plate
teknova
cfu
quantifi
antifung
activ
caspofungin
fluconazol
evalu
biofilm
c
albican
essenti
describ
pierc
et
briefli
biofilm
establish
h
preadhes
h
adher
h
matur
develop
ad
yeast
cell
well
flatbottom
microtit
plate
costar
corn
ny
fifti
aliquot
serial
dilut
peptid
antifung
drug
ad
well
triplic
incub
h
h
prior
analysi
biofilm
metabol
activ
concentr
reagent
use
follow
fluco
caspo
analysi
effect
agent
candida
biofilm
perform
use
xtt
colorimetr
one
hundr
xttmenadion
ad
biofilm
well
plate
incub
dark
h
supernat
transfer
new
flatbottom
microtit
plate
greiner
bioon
monro
nc
absorb
measur
nm
molecular
devic
read
plot
averag
triplic
subtract
correspond
valu
neg
control
xttmenadion
balbc
femal
mice
week
old
femal
mice
week
old
obtain
charl
river
laboratori
alloc
randomli
group
five
mice
per
cage
mice
maintain
h
lightdark
cycl
thermostat
control
room
durat
experi
c
albican
inocula
prepar
fresh
day
satur
cultur
grown
overnight
ypd
medium
wash
steril
pb
fungi
count
hemocytomet
stock
suspens
prepar
steril
pb
balbc
mice
challeng
cfuml
wildtyp
c
albican
refer
strain
mice
challeng
cfuml
ml
c
albican
clinic
isol
iv
inject
later
caudal
tail
vein
use
g
inch
needl
anim
treat
iv
sc
ip
rout
immedi
postinfect
pi
h
pi
steril
salin
control
fluconazol
caspofungin
administ
concentr
indic
ml
mice
weight
monitor
daili
gener
clinic
condit
mice
euthan
approv
usc
iacuc
complianc
nation
institut
health
guid
care
use
laboratori
anim
experi
repeat
least
three
time
assess
system
fungal
clearanc
renal
fungal
burden
determin
mice
euthan
time
indic
kidney
weigh
homogen
ml
steril
pb
serial
dilut
homogen
plate
ypd
agar
plate
incub
day
cfu
per
gram
kidney
calcul
singl
dose
pk
evalu
quantifi
plasma
peptid
concentr
interv
follow
mgkg
bolu
inject
administ
iv
ip
mice
indic
interv
plasma
prepar
edtaanticoagul
blood
collect
asept
termin
cardiac
punctur
plasma
dilut
acetonitril
plasma
concentr
determin
reversephas
liquid
chromatographi
xbridg
phenyl
column
water
acquiti
hclass
uplc
water
tandem
electrospray
mass
spectroscopi
xevo
tq
run
masslynx
water
quantit
mass
spectroscopi
perform
multiplereact
monitor
transit
area
curv
determin
targetlynx
water
pharmacokinet
model
intraven
concentrationtim
data
perform
adapt
version
softwar
use
pool
data
approach
one
twocompart
model
evalu
model
select
base
akaik
inform
criterion
aic
bayesian
inform
criterion
bic
score
likelihood
ratio
test
lrt
goodnessoffit
plot
concentr
data
lower
limit
quantit
treat
miss
pharmacokinet
analysi
area
curv
calcul
take
averag
concentr
time
point
appli
linear
trapezoid
method
bioavail
f
ip
inject
determin
use
ratio
auc
ip
iv
edtaanticoagul
blood
collect
asept
termin
cardiac
punctur
analyz
complet
blood
cell
count
use
hemavet
fs
hematolog
analyz
drew
scientif
plasma
cytokin
level
plasma
quantifi
use
mousespecif
milliplex
map
kit
millipor
surviv
curv
compar
use
log
rank
mantelcox
test
blood
level
pmn
monocyt
plasma
level
cytokin
compar
use
mannwhitney
test
oneway
anova
use
analysi
varianc
fungal
burden
data
follow
uncorrect
fisher
least
signific
differ
lsd
test
signific
surviv
endpoint
calcul
analysi
fig
statist
analys
employ
graphpad
prism
